全文获取类型
收费全文 | 6038篇 |
免费 | 517篇 |
国内免费 | 140篇 |
专业分类
耳鼻咽喉 | 39篇 |
儿科学 | 116篇 |
妇产科学 | 31篇 |
基础医学 | 652篇 |
口腔科学 | 9篇 |
临床医学 | 980篇 |
内科学 | 2304篇 |
皮肤病学 | 12篇 |
神经病学 | 130篇 |
特种医学 | 94篇 |
外科学 | 831篇 |
综合类 | 526篇 |
一般理论 | 1篇 |
预防医学 | 283篇 |
眼科学 | 6篇 |
药学 | 305篇 |
15篇 | |
中国医学 | 36篇 |
肿瘤学 | 325篇 |
出版年
2024年 | 25篇 |
2023年 | 492篇 |
2022年 | 713篇 |
2021年 | 1033篇 |
2020年 | 961篇 |
2019年 | 372篇 |
2018年 | 264篇 |
2017年 | 258篇 |
2016年 | 270篇 |
2015年 | 242篇 |
2014年 | 416篇 |
2013年 | 274篇 |
2012年 | 180篇 |
2011年 | 139篇 |
2010年 | 201篇 |
2009年 | 176篇 |
2008年 | 65篇 |
2007年 | 91篇 |
2006年 | 75篇 |
2005年 | 49篇 |
2004年 | 43篇 |
2003年 | 36篇 |
2002年 | 35篇 |
2001年 | 36篇 |
2000年 | 18篇 |
1999年 | 39篇 |
1998年 | 37篇 |
1997年 | 23篇 |
1996年 | 33篇 |
1995年 | 23篇 |
1994年 | 18篇 |
1993年 | 16篇 |
1992年 | 5篇 |
1991年 | 11篇 |
1990年 | 10篇 |
1989年 | 9篇 |
1988年 | 4篇 |
1985年 | 2篇 |
1984年 | 1篇 |
排序方式: 共有6695条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
6.
7.
《Journal of infection and chemotherapy》2022,28(4):548-553
IntroductionCOVID-19 patients have been reported to have digestive symptoms with poor outcome. Ivermectin, an antiparasitic drug, has been used in COVID-19 patients. The objective of this study was to evaluate whether ivermectin has effects on gastrointestinal complications and ventilator-free days in ventilated patients with COVID-19.MethodsCOVID-19 patients who were mechanically ventilated in the ICU were included in this study. The ventilated patients who received ivermectin within 3 days after admission were assigned to the Ivermectin group, and the others were assigned to the Control group. Patients in the Ivermectin group received ivermectin 200 μg/kg via nasal tube. The incidence of gastrointestinal complications and ventilator-free days within 4 weeks from admission were evaluated as clinical outcomes using a propensity score with the inverse probability weighting method.ResultsWe included 88 patients in this study, of whom 39 patients were classified into the Ivermectin group, and 49 patients were classified into the Control group. The hazard ratio for gastrointestinal complications in the Ivermectin group as compared with the Control group was 0.221 (95% confidence interval [CI], 0.057 to 0.855; p = 0.029) in a Cox proportional-hazard regression model. The odds ratio for ventilator-free days as compared with the Control group was 1.920 (95% CI, 1.076 to 3.425; p = 0.027) in a proportional odds logistic regression model.ConclusionsIvermectin improved gastrointestinal complications and the number of ventilator-free days in severe COVID-19 patients undergoing mechanical ventilation. Prevention of gastrointestinal symptoms by SARS-Cov-2 might be associated with COVID-19 outcome. 相似文献
8.
目的:探讨环状RNA hsa_circ_0006867在结直肠癌中的表达及其与临床病理因素的关系。方法:全转录组测序筛选结直肠癌中特异circRNAs表达谱,挑选出差异表达显著的hsa_circ_0006867,qRT-PCR检测54例结直肠癌组织及癌旁组织中hsa_circ_0006867表达情况,分析其表达水平与结直肠癌临床病理特征的相关性,ROC曲线分析hsa_circ_0006867在结直肠癌中的诊断价值。结果:测序获得circRNAs在结直肠癌中的差异表达谱,qRT-PCR验证hsa_circ_0006867在结直肠癌中表达下调(P<0.05)。其表达水平与肿瘤分化程度和远处转移有关(P<0.05)。ROC曲线显示hsa_circ_0006867诊断结直肠癌AUC为0.851(95%CI:0.775~0.927),当截断值为0.0146时,敏感度为88.46%(95%CI:0.770~0.946),特异度为73.08%(95%CI:0.598~0.832),差异具有统计学意义(P<0.001)。结论:hsa_circ_0006867在结直肠癌中表达下调,与相关临床病理特征密切联系,可作为潜在结直肠癌临床诊断指标。 相似文献
9.
《Journal of cystic fibrosis》2022,21(6):1066-1069
Elexacaftor/tezacaftor/ivacaftor (ELX-TEZ-IVA) is a Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) modulator shown to improve lung function and reduce sweat chloride in people with Cystic Fibrosis (CF). The only commonly reported dermatologic adverse effect with CFTR modulators including ELX-TEZ-IVA is rash. In this case series, we describe 19 patients who reported new onset or worsening of acne after initiation of this drug to their CF pharmacist or another member of their CF care team. The mechanism and frequency of this adverse effect is unknown. 相似文献
10.